Association of gain of 1q21 with hematologic parameters
| . | Overall study population, patient groups 1-4, n = 231 . | AL amyloidosis series, patient groups 1-2, n = 85 . | ||||
|---|---|---|---|---|---|---|
| Gain 1q21 . | No gain 1q21 . | P . | Gain 1q21 . | No gain 1q21 . | P . | |
| Intact immunoglobulin by immunofixation, no. patients (%) | 40/44 (91) | 122/166 (73) | .12 | 15/19 (79) | 26/65 (40) | .03 |
| Lambda light chain restriction, no. patients (%) | 34/44 (77) | 81/165 (49) | .01 | 18/19 (95) | 45/65 (69) | .29 |
| Median involved FLC concentration, mg/L | ND | ND | ND | 231 | 204 | 1.0 |
| Median plasma cell content, % | 11 | 9 | .002 | 11 | 9 | .55 |
| . | Overall study population, patient groups 1-4, n = 231 . | AL amyloidosis series, patient groups 1-2, n = 85 . | ||||
|---|---|---|---|---|---|---|
| Gain 1q21 . | No gain 1q21 . | P . | Gain 1q21 . | No gain 1q21 . | P . | |
| Intact immunoglobulin by immunofixation, no. patients (%) | 40/44 (91) | 122/166 (73) | .12 | 15/19 (79) | 26/65 (40) | .03 |
| Lambda light chain restriction, no. patients (%) | 34/44 (77) | 81/165 (49) | .01 | 18/19 (95) | 45/65 (69) | .29 |
| Median involved FLC concentration, mg/L | ND | ND | ND | 231 | 204 | 1.0 |
| Median plasma cell content, % | 11 | 9 | .002 | 11 | 9 | .55 |
Table shows the association of the CA t(11;14) and gain 1q21 with hematologic parameters [n/N(%)]. Effects could be shown for the detection of an intact immunoglobulin, light chain restriction, and bone marrow plasmocytosis.
FLC indicates free light chain; ND, not determined.